logo

Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice

Naomi Clements, Michelle Hui, Brent Skippen

Purpose

To compare results of Ranibizumab vs Aflibercept for the treatment of nAMD, DMO and RVO and ascertain variations in clinical outcomes in a rural setting.

Methods

Retrospective observational cohort study assessing 106 eyes from 84 patients over 18 months. Primary outcome measures are anatomical (central macular thickness - CMT) and functional (visual acuity - VA), secondary outcomes include number of injections and overall safety profile. Statistical analyses (repeated measure ANOVA, chi-square analysis and Bonferroni post-hoc test) conducted with SPSS. Significance level set at p<.10

Results

For nAMD, VA and CMT results were comparable between Ranibizumab and Aflibercept. More ‘dry’ OCT outcomes occurred with Ranibizumab. Similar VA and CMT results occurred with DMO treatment, except for significantly more ‘dry’ OCT outcomes with Aflibercept in those DMO patients with prior injections. For RVO patients, while anatomical results were comparable, VA improved significantly with Ranibizumab, not Aflibercept. More ‘dry’ OCT outcomes were achieved with Ranibizumab.

Demographic analysis showed a mean age of 76 years, 57.5% female. Overall average of 7 injections in 12 months. One serious adverse event was recorded (myocardial infarction) with Ranibizumab for nAMD.

Discussion

There were no significant differences in functional or anatomical outcomes between Ranibizumab and Aflibercept for treatment of nAMD and DMO. Ranibizumab showed statistically significant improvement in outcomes over Aflibercept in treatment of RVO. To the best of our knowledge, this study is the first of its kind in a rural Australian setting

November, 2020
10.37912/WaggaJOM.0201.12

Subscribe to our newsletter

Latest Articles
Admin Editor,
December, 2024
Research
Cost-Effective Analysis of Inflammatory Bowel Disease Models of Care, A Rural Perspective
Dr Thomas Skinner, BSci, M.D. Dr Symret Singh, BCom M.D. , Dr Nishmi Gunasingam Introduction Unlike many chronic conditions, Inflammatory Bowel Disease (IBD) are often...
Admin Editor,
December, 2024
Research
Can artificial intelligence play a role in the analysis of non-gated, non-cardiac CT?
Jack Evans, Professor Joseph Suttie Abstract The rapid development of artificial intelligence (AI) has offered an opportunity to improve processing time and diagnostic accuracy of radiological images (1). Deep...
Admin Editor,
December, 2024
Research
Asthma Morbidity and its Association with Socioeconomic Status in the Australian Population
Dr. Matin Zohoori Niya, Dr. Joanne Hart, Dr. Rajneesh Kaur Background Asthma Australia reports that prevalence of asthma is highest among people living in the lowest socioeconomic areas. Studies...
Admin Editor,
December, 2024
Research
The Many Fronts of Heart Failure Monitoring – An Observational Study into Heart Failure Patients using Right Heart Catheterisation and Pulse Wave Analysis
Billy Poulden, Dr Audrey Adji, Professor Christopher Hayward Introduction Heart failure (HF) is a condition that occurs when a person’s heart is unable to pump enough blood to adequately...
Admin Editor,
December, 2024
Research
Outcomes of Telepsychiatry in Australia, a clinical review
Helen Devery and Peter Sheeran Introduction Use of telephone and videoconferencing technologies by psychiatrists is a frequently proposed solution to address lack of resourcing and staff shortages in regional...